Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first subject, earning Arrowhead a $15 million milestone payment, in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457, previously known…